(a) Peripheral blood smear in a patient with the chronic phase of chronic myeloid leukemia (CML) before treatment; (b) Detection of BCR::ABL1 fusion gene, p210 by RNA sequencing; (c) Peripheral blood ...

Molecular and genetic testing has become a game-changer in brain tumor care - shaping diagnosis, guiding treatments and opening doors to new therapies. Once available to a handful of patients, these ...

Rare diseases are genetic disorders that affect a small proportion of the population. Despite their rarity, they can be a ...

Current Practices, Perceived Barriers, and Promising Implementation Strategies for Improving Quality of Smoking Cessation Support in Accredited Cancer Programs of the American College of Surgeons This ...

During the COVID-19 health emergency, two strategies for detecting coronavirus infections were commonly adopted around the world. Part of Nature Outlook: Medical diagnostics Initially, in countries ...

Genetic variants that cause rare disorders may remain elusive even after expansive testing, such as exome sequencing. The diagnostic yield of genome sequencing, particularly after a negative ...

In a recent blog, I discussed the change in nomenclature for the conditions formerly known as Neurofibromatosis type 2 (NF2) and schwannomatosis. This change was based on the results of an ...

Integration of AI with image-based genomics, consolidation towards integrated platforms, and growing focus on companion diagnostics bolster growthDublin, Jan. 21, 2026 (GLOBE NEWSWIRE) -- The ...

PARSIPPANY, NJ, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, (“Interpace” or the “Company”) (OTCQX: IDXG) today responded to the final Local ...

Fulgent Genetics agrees to buy StrataDx and assets from Bako Diagnostics for $55.5 million. Learn how this cash deal expands ...